Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-06 6:02 pm Purchase |
2025-02-27 | 13G | Tyra Biosciences, Inc. TYRA |
TCG Crossover GP I, LLC | 2,898,103 5.700% |
2,898,103 (New Position) |
Filing History |
| 2025-02-14 4:44 pm Sale |
2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
TCG Crossover GP I, LLC | 0 0.000% |
-1,555,118 (Position Closed) |
Filing History |
| 2025-02-14 4:23 pm Purchase |
2024-12-31 | 13G | Upstream Bio, Inc. UPB |
TCG Crossover GP I, LLC | 2,801,763 5.200% |
2,801,763 (New Position) |
Filing History |
| 2024-11-13 4:25 pm Sale |
2024-09-30 | 13G | AN2 Therapeutics, Inc. ANTX |
TCG Crossover GP I, LLC | 1,555,118 5.200% |
-1,123,091 (-41.93%) |
Filing History |
| 2024-04-19 7:09 pm Purchase |
2024-04-11 | 13G | ABIVAX SA ABVX |
TCG Crossover GP I, LLC | 6,056,596 9.600% |
6,056,596 (New Position) |
Filing History |
| 2024-04-01 4:14 pm Sale |
2024-03-28 | 13D | KalVista Pharmaceuticals, Inc. KALV |
TCG Crossover GP I, LLC | 1,345,826 3.200% |
-1,355,014 (-50.17%) |
Filing History |
| 2024-02-20 4:49 pm Sale |
2024-02-07 | 13D | KalVista Pharmaceuticals, Inc. KALV |
TCG Crossover GP I, LLC | 2,700,840 6.520% |
-707,241 (-20.75%) |
Filing History |
| 2024-02-13 4:27 pm Sale |
2023-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY |
TCG Crossover GP I, LLC | 0 0.000% |
-5,905,400 (Position Closed) |
Filing History |
| 2024-02-09 4:31 pm Purchase |
2024-01-29 | 13G | CG Oncology, Inc. Common stock CGON |
TCG Crossover GP I, LLC | 3,570,206 5.400% |
3,570,206 (New Position) |
Filing History |
| 2024-02-09 4:29 pm Purchase |
2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
TCG Crossover GP I, LLC | 2,678,209 9.000% |
1,388,889 (+107.72%) |
Filing History |
| 2024-02-09 4:28 pm Purchase |
2023-06-16 | 13G | Aerovate Therapeutics, Inc. AVTE |
TCG Crossover GP I, LLC | 2,201,274 8.000% |
2,201,274 (New Position) |
Filing History |
| 2024-02-09 4:24 pm Sale |
2023-12-31 | 13G | Taysha Gene Therapies, Inc. TSHA |
TCG Crossover GP I, LLC | 2,912,861 1.600% |
-8,198,250 (-73.78%) |
Filing History |
| 2024-02-09 4:22 pm Purchase |
2024-01-29 | 13G | Tourmaline Bio, Inc. TRML |
TCG Crossover GP I, LLC | 1,477,593 5.900% |
1,477,593 (New Position) |
Filing History |
| 2024-02-09 4:22 pm Purchase |
2023-12-31 | 13G | Cogent Biosciences, Inc. COGT |
TCG Crossover GP I, LLC | 5,631,042 6.500% |
2,000,000 (+55.08%) |
Filing History |
| 2023-08-28 4:08 pm Purchase |
2023-08-18 | 13G | COMPASS Pathways plc CMPS |
TCG Crossover GP I, LLC | 6,437,497 9.900% |
6,437,497 (New Position) |
Filing History |
| 2023-08-25 4:22 pm Purchase |
2023-08-16 | 13G | Taysha Gene Therapies, Inc. TSHA |
TCG Crossover GP I, LLC | 11,111,111 5.900% |
11,111,111 (New Position) |
Filing History |
| 2023-07-25 4:19 pm Purchase |
2023-06-26 | 13G | AN2 Therapeutics, Inc. ANTX |
TCG Crossover GP I, LLC | 1,289,320 6.600% |
1,289,320 (New Position) |
Filing History |
| 2023-07-25 4:18 pm Purchase |
2023-05-25 | 13G | Icosavax, Inc. ICVX |
TCG Crossover GP I, LLC | 3,703,704 7.500% |
3,703,704 (New Position) |
Filing History |
| 2023-07-25 4:17 pm Purchase |
2023-07-17 | 13G | Savara Inc. SVRA |
TCG Crossover GP I, LLC | 10,000,000 7.400% |
10,000,000 (New Position) |
Filing History |
| 2023-02-14 2:23 pm Purchase |
2022-12-31 | 13G | Cogent Biosciences, Inc. COGT |
TCG Crossover GP I, LLC | 3,631,042 5.200% |
3,631,042 (New Position) |
Filing History |